Capsule Filler Allows Multiple Configurations
The Planeta 200 Capsule Filler’s modular design can be configured for a variety of production requirements.
MG America’s Planeta 200 Capsule Filler produces up to 200,000 capsules per hour. Its modular design can be configured for a variety of production requirements, fitting several dosing units simultaneously and enabling one capsule to be filled with differing products. The filler reduces product waste and exposure to the greater processing environment.
The Planeta 200 also is scalable. It can be configured for medium speeds and upgraded later for maximum speeds, reaching different performance levels depending on the number and type of dosing units installed. Its weight control system also can be upgraded post-installation, including statistical control of capsule gross weight and the MultiNETT system, which allows in-process net weight checks of each capsule and each dosed product. Planeta 200 can also be equipped with isolators satisfying different containment levels and washing systems. MG America is showcasing the Planeta 200 at INTERPHEX 2016.
Source: MG America
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
